Inipharm is a biopharmaceutical company dedicated to developing innovative therapies for severe liver diseases, with a particular focus on the genetically-defined target HSD17B13. This target has been extensively validated through research indicating that genetic variants affecting HSD17B13 expression correlate with significantly lower rates and severity of various liver diseases. Inipharm is advancing a pipeline of small-molecule inhibitors designed to modulate the activity of HSD17B13, which has been identified as a novel target for conditions such as non-alcoholic steatohepatitis (NASH). The company's research demonstrates that these inhibitors exhibit anti-fibrotic effects in human liver cell models, suggesting their potential efficacy in treating fibrotic liver diseases.

The scientific foundation of Inipharm's approach is rooted in the understanding of HSD17B13's role in critical biological pathways associated with lipotoxicity, inflammation, and fibrosis. The company leverages insights from genome-wide association studies that highlight the protective effects of loss-of-function variants in HSD17B13 against liver disease. By targeting this protein, Inipharm aims to address significant unmet medical needs in the treatment of severe liver conditions, thereby contributing to advancements in the biopharmaceutical landscape focused on liver health.

United States

Inipharm is a biopharmaceutical company focused on discovering and developing therapies for severe liver diseases. Inipharm's lead program is focused on the highly validated, genetically-defined target, HSD17B13.

There is extensive, consistent evidence that genetic variants in expression of HSD17B13 are associated with significantly lower rates and severity of multiple liver diseases. Building on these novel insights into the biologic activity of HSD17B13, Inipharm is advancing a pipeline of small-molecule therapies that target the activity of this protein.

Inipharm

Company Details